JC Virus-DNA Detection Is Associated with CD8 Effector Accumulation in Peripheral Blood of Patients with Multiple Sclerosis under Natalizumab Treatment, Independently from JC Virus Serostatus

Figure 1

Discordance between the Stratify JCV assay and JCV-DNA detection in blood and urine samples. The pie charts represent the percentages of concordance and discordance between JCV antibody (Ab) and JCV-DNA detection in urine and plasma. Percentages of double positive JCV-DNA+ and JCV-Ab+ cases: 21% (4/19), 12% (6/50), 16.7% (7/42), 28.6% (4/14), and 33.3% (2/6) at 0, 12, 24, 36, and , respectively. Percentages of JCV-DNA− and JCV-Ab+ cases: 21% (4/19), 18% (9/50), 23,8% (10/42), 21.4% (3/14), and 50% (3/6) of cases at 0, 12, 24, 36, and , respectively. Percentages of cases with double negative JCV-DNA− and JCV-Ab−: 36,8% (7/19), 58% (29/50), 42,9% (18/42), 35.7% (5/14), and 16.7% (1/6) of cases at 0, 12, 24, 36, and , respectively. Percentages of discordant cases with JCV-DNA+ and JCV-Ab− (separated sector): 21.1% (4/19), 12% (6/50), 16.7% (7/42), 14.3% (2/14), and 0% (0/6) of cases at 0, 12, 24, 36, and , respectively. 0: 0 infusions, 12: from 1 to 12 infusions, 24: from 13 to 24 infusions, 36: from 25 to 36 infusions, and : over 36 infusions of natalizumab.